Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christian Mende

La Jolla, CA Medical Doctor

NPI 1518983915 CMS profile 1381030

6950 Fairway Rd, La Jolla, CA 92037

Open in the dashboard

General payments

$1,473,526

1,831 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christian Mende of La Jolla, CA is reported in the CMS Open Payments database as having received $1,473,526 across 1,831 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $224,832 255
2024 General $345,713 421
2023 General $241,209 280
2022 General $67,044 75
2021 General $233,679 285
2020 General $85,474 114
2019 General $275,574 401

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christian Mende
  • California median
  • Middle half of California
  • National median

In program year 2025, general payments to Christian Mende were reported at $224,832. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.

Show as a table
Year Christian Mende California median Middle half National median
2019 $275,574 $161 $50–$652 $163
2020 $85,474 $114 $34–$392 $114
2021 $233,679 $137 $41–$509 $132
2022 $67,044 $152 $48–$573 $149
2023 $241,209 $162 $50–$581 $160
2024 $345,713 $162 $52–$583 $164
2025 $224,832 $172 $54–$610 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $473,370 654 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $301,842 284 payments
  3. Lilly USA, LLC $230,597 329 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $211,714 273 payments
  5. Janssen Pharmaceuticals, Inc $137,577 143 payments
  6. Novo Nordisk Inc $72,203 69 payments
  7. Eli Lilly and Company $18,292 10 payments
  8. Scpharmaceuticals Inc. $7,057 5 payments
  9. CutisPharma, Inc. $5,999 8 payments
  10. Janssen Scientific Affairs, LLC $5,629 16 payments
  11. Other $9,246 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,191,599 579 payments
  2. Travel and Lodging $142,437 551 payments
  3. Consulting Fee $95,444 52 payments
  4. Food and Beverage $43,687 644 payments
  5. Education $359 5 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $423,552 572 payments
  2. Kerendia $298,392 276 payments
  3. JARDIANCE Diabetes $225,975 308 payments
  4. INVOKANA $134,163 151 payments
  5. JARDIANCE Diabetes $98,414 129 payments
  6. JARDIANCE Diabetes $90,227 95 payments
  7. Ozempic $71,565 62 payments
  8. LOKELMA $48,404 59 payments
  9. FUROSCIX $7,057 5 payments
  10. WIDAPLIK $5,999 8 payments
  11. Other $9,120 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

1,831 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record